Neupogen® (Filgrastim): General Information for Clinicians

Centers for Disease Control and Prevention, National Center for Environmental Health. 12/10/2015This resource provides information about Neupogen (Filgrastim), which was approved in March 2015 by the U.S. Food and Drug Administration (FDA) to treat people who have received high doses of radiation. Neupogen is a drug that has been used successfully for cancer patients to produce more white blood cells. The fact sheet discusses who can take Neupogen, how it is given, and its side effects. (Text)

Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 28, 2016 Category: Global & Universal Authors: The U.S. National Library of Medicine Source Type: news